Evidence map›Paper›PMID 34287742›Full record

ArticleSurgical case reports2021

Chemotherapy resumption in breast cancer patient after COVID-19.

Julian Horiguchi, Ayako Nakashoji, Naoki Kawahara, Akira Matsui, Takayuki Kinoshita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julian HoriguchiDepartment of Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.
Ayako NakashojiDepartment of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan. ayako.nakashoji@gmail.com.ORCID http://orcid.org/0000-0003-2443-6995
Naoki KawaharaDepartment of Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.
Akira MatsuiDepartment of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.
Takayuki KinoshitaDepartment of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.
Tokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2. CASE PRESENTATION: The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy.

conclusionsEvaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient's post-COVID-19.

Indexed as

Breast cancerCase reportChemotherapyCOVID-19ResumptionSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID34287742
PMCPMC8294251
OpenAlexW3184199681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.